When the bourses closed last evening, Amit Bakshi was worth Rs 3,225 crore and Eris Lifesciences, a pharmaceutical company he founded 10 years ago, became a legitimate unicorn. The most profitable, fastest-growing pharma company in five years with the handsomest return on capital employed—the descriptors have been glowing, even as the industry prospects have dimmed of late. The Indian pharma index has been consistently down since 2016, its first decline in five years. And the pall of the US regulatory inspections and warnings hang heavy on all exporting companies.

“No sane person could have done a pharma IPO today,” Bakshi told me soon after the issue closed on 20 June. “Imagine if this [IPO] was done seven-eight months ago, the amount of explanation I’ve had to offer would have been only 10%. Now, everyone wanted 2X-3X understanding because the times are not crazy.”

Bakshi has diluted only 0.5% of his stake so, in his own words, it doesn’t make “much difference” to his life. (Except it has made him richer by Rs 41.45 crore.) Conversely, though, it makes a difference to the pharmaceutical sector, which has not seen a company grow from scratch to this scale in a span of 10 years. Except perhaps for Mankind Pharma, which is now 21 years old.

Eris makes specialty drugs, which is a subset of the crowded branded generics market. Close to 200,000 brands sell in the Indian market of which brands yielding more than Rs 10 lakh in annual sales are just about 70,000-80,000. That’s still crowded considering how they jostle for a few minutes of attention in a doctor’s clinic. Into that space, Bakshi made an entry in 2007 with an eye for spotting product gaps and launching new brands in chronic diseases like cardiology, diabetes gastroenterology and others. As much as 96% of its prescriptions are written by specialists, even today. In 2012, when I spoke with him for a special edition of Hidden Gems in Forbes India, Bakshi was indeed hidden. Reticent, and somewhat shy, he admitted it was his first media interaction ever. He says he was discovering the product differentiation then, he has “mastered it” now.

I have done no networth calculation. When I was on the road shows, at one point I felt it was too good to believe

Amit Bakshi

Going public was a decision, guided not by the company’s need for funds but the private equity investor, ChrysCapital’s need for an exit. The existing fund was nearing its end, and Chrys had to raise a new fund. Moreover, secondary sales are not always possible, and strategic sales, another exit option, happen only when the investor has substantial equity in the company, says Sunil Thakur, director and chief operating officer at Quadria Capital, which has multiple investments in pharma.

AUTHOR

Seema Singh

Seema has over two decades of experience in journalism. Before starting The Ken, Seema wrote “Myth Breaker: Kiran Mazumdar-Shaw and the Story of Indian Biotech”, published by HarperCollins in May 2016. Prior to that, she was a senior editor and bureau chief for Bangalore with Forbes India, and before that she wrote for Mint. Seema has written for numerous international publications like IEEE-Spectrum, New Scientist, Cell and Newsweek. Seema is a Knight Science Journalism Fellow from the Massachusetts Institute of Technology and a MacArthur Foundation Research Grantee.

View Full Profile

Subscribe to read this story

The Ken is the only business subscription you need. Questions?

 

Premium

  • 5 original and reported longform business stories every week
  • Access to ONLY India edition
  • Close to 250 exclusive stories every year
  • Full access to over 5 years of paywalled stories
  • Pick up to 5 premium subscriber newsletters
  • 4 original and reported longform business stories each week
  • Access to ONLY Southeast Asia edition
  • Close to 200 exclusive stories every year
  • Full access to all paywalled stories since March 2020
  • Pick up to 5 premium subscriber newsletters

Rs. 2,750 /year

$ 120 /year

India Edition
Subscribe Subscribe
Most Asked For

Borderless

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories

Rs. 4,200 /year

Subscribe
 

Echelon

  • 8 original and reported longform business stories each week
  • Access to both India and Southeast Asia editions
  • Close to 400 exclusive stories every year
  • Full access to over 5 years of paywalled stories across India and Southeast Asia
  • Unlimited access to all premium subscriber newsletters
  • Visual Stories
  • Bonus annual gift subscription
  • Priority access to all new products and features

Rs. 8,474 /year

Subscribe
Or

Questions?

What kind of subscription plans do you offer?

We have three types of subscriptions
- Premium which gives you access to either the India or the Southeast Asia edition.
- Borderless which gives you complete access to The Ken across both editions
- Echelon which gives you complete access to The Ken across both editions along with a bonus gift subscription

What do I get if I subscribe?

The Premium edition gives you access to stories in that edition along with any five subscriber-only newsletters of your choice.

The Borderless and Echelon subscription gives you complete access to The Ken across editions and unlimited access to as many newsletters as you like.

What topics do you usually write about?

We publish sharp, original and reported stories on technology, business and healthcare. Our stories are forward-looking, analytical and directional — supported by data, visualisations and infographics. We use language and narrative that is accessible to even lay readers. And we optimise for quality over quantity, every single time.

Our specialised subscriber-only newsletters are written by our expert, award-winning journalists and cover a range of topics across finance, retail, clean energy, cryptocurrency, ed-tech and many more.

How many newsletters do you have?

We are constantly adding specialised subscriber-only newsletters all the time. All of these are written by our team of award-winning journalists on a specialised topic.

You can see the list of newsletters that we publish over here.

Does a Premium subscription to your Indian edition get me access to the Southeast Asia edition? Or vice-versa?

Afraid not. Each edition is separate with its own subscription plan. The India edition publishes stories focused on India. The Southeast Asia edition is focused on Southeast Asia. We may occasionally cross-publish stories from one edition to the other.

We recommend the Borderless or the Echelon Plan which will give you access to stories across both editions.

Do you have a mobile app?

Yes! We have a top-rated mobile app on both iOS and Android which allows you to read on-the-go and has some amazing features like the ability to bookmark stories, save on your device, dark mode, and much more. It’s really the best way to read The Ken.

Is there a free trial?

You can sign up for a free account to experience The Ken and understand our products better. We’ll send you some free stories and newsletters occasionally, and you can access our archive of previously published free stories. You can stay on the free account as long as you’d like.

The vast majority of our stories, articles and newsletters can be accessed only by a paid subscription.

Do you offer any discounts?

Sorry, no. Our journalism is funded completely by our subscribers. We believe that quality journalism comes at a price, and readers trust and pay us so that we can remain independent.

Do you offer refunds?

No. We allow you to sample our journalism for free before signing up, and after you do, we stand by its quality. But we do not offer refunds.

I am facing some trouble purchasing a subscription. What can I do?

Just write to us at [email protected] with details. We’ll help you out.

I have a few more questions. How can I reach out to you?

Sure. Just email us at [email protected] or follow us on Twitter.